02176nas a2200457 4500000000100000008004100001260001300042653003000055653002500085653001000110653000900120653001100129653001600140653001200156653003300168653003000201653001100231653002200242653001900264653001100283653002300294653001200317653000900329653002000338653001600358653002600374653001300400653002500413653002200438653001800460100001300478700001600491700001500507700001700522700002000539245009200559300001100651490000800662520103400670022001401704 2011 d c2011 Oct 10 aAdministration, Cutaneous 10 aAdministration, Oral 10 aAdult 10 aAged 10 aBiopsy 10 aClofazimine 10 aDapsone 10 aDrug Administration Schedule 10 aDrug Therapy, Combination 10 aFemale 10 aFollow-Up Studies 10 aHealth Surveys 10 aHumans 10 aLeprostatic Agents 10 aleprosy 10 aMale 10 aMedical Records 10 aMiddle Aged 10 aRetrospective Studies 10 aRifampin 10 aSecondary Prevention 10 aTreatment Outcome 10 aUnited States 1 aDacso MM 1 aJacobson RR 1 aScollard D 1 aStryjewska B 1 aPrestigiacomo J 00 aEvaluation of multi-drug therapy for leprosy in the United States using daily rifampin. a689-94 0 v104 3 aOBJECTIVES: To evaluate the occurrence of relapse of multibacillary leprosy after multi-drug treatment including daily rifampin.
METHODS: A retrospective review was performed utilizing data from the National Hansen's Disease Program (NHDP) on patients with leprosy treated and followed from 1988-1997 who received multi-drug therapy including daily rifampin. The occurrence of relapse in this cohort was measured, and demographic data and various clinical variables were also gathered.
RESULTS: Ultimately, 158 cases fulfilled the eligibility criteria. 77% of cases were multibacillary patients and were treated with 2 or 3 drug protocols at rates of 36% and 35% before and after 1992, respectively. Only one case of relapse was found, and this patient underwent 2-drug therapy versus 3-drug therapy.
CONCLUSION: These data are remarkable for the absence of relapse with daily rifampin, as contrasted with the published experience using the WHO protocol with monthly rifampin.
a1541-8243